Yegorov et al.

MALDI-MS/ML to detect ARI

1	Application of MALDI-MS and Machine Learning to Detection of SARS-CoV-2 and non-SARS-CoV-2
2	Respiratory Infections.

3

4	Sergey Yegorov ^{1,2*} , Irina Kadyrova ^{3*} , Ilya Korshukov ³ , Aidana Sultanbekova ³ , Valentina Barkhanskaya ³ ,						
5	Tatiana Bashirova ⁶ , Yerzhan Zhunusov ⁷ , Yevgeniya Li ⁷ , Viktoriya Parakhina ^{7,8} , Svetlana Kolesnichenko ³ ,						
6	Yeldar Baiken ^{2,4,5} , Bakhyt Matkarimov ⁴ , Dmitriy Vazenmiller ³ , Matthew S. Miller ¹ , Gonzalo H. Hortelano ² ,						
7	Anar Turmuhambetova ³ , Antonella E. Chesca ⁹ , Dmitriy Babenko ³ .						
8							
9	¹ Michael G. DeGroote Institute for Infectious Disease Research; McMaster Immunology Research Centre;						
10	Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.						
11	² School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan						
12	³ Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.						
13	⁴ National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Astana, Kazakhstan.						
14	⁵ School of Engineering and Digital Sciences, Nazarbayev University, Astana, Kazakhstan.						
15	⁶ City Centre for Primary Medical and Sanitary Care, Karaganda, Kazakhstan.						
16	⁷ Infectious Disease Centre of the Karaganda Regional Clinical Hospital, Karaganda, Kazakhstan.						
17	⁸ Department of Internal Diseases, Karaganda Medical University, Kazakhstan.						
18	⁹ Faculty of Medicine, Transilvania University, Brașov, Romania						
19							
20	* Corresponding authors' contact emails:						
21	yegorovs@mcmaster.ca (SY)						
22	ikadyrova@qmu.kz (IK)						
23							
24							

Keywords: Acute respiratory infection; COVID-19; SARS-CoV-2; MALDI-MS; Machine Learning; NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

perpetuity. It is made available under a CC-BY 4.0 International license .

Yegorov et al.

MALDI-MS/ML to detect ARI

26 Abstract

- 27 Background: Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) could aid the diagnosis of acute respiratory infections (ARI) owing to its affordability and high-throughput capacity. 28 MALDI-MS has been proposed for use on commonly available respiratory samples, without specialized 29 sample preparation, making this technology especially attractive for implementation in low-resource regions. 30 31 Here, we assessed the utility of MALDI-MS in differentiating SARS-CoV-2 versus non-COVID acute respiratory infections (NCARI) in a clinical lab setting of Kazakhstan. 32 33 Methods: Nasopharyngeal swabs were collected from in- and outpatients with respiratory symptoms and from asymptomatic controls (AC) in 2020-2022. PCR was used to differentiate SARS-CoV-2+ and NCARI 34 35 cases. MALDI-MS spectra were obtained for a total of 252 samples (115 SARS-CoV-2+, 98 NCARI and 39 AC) without specialized sample preparation. In our first sub-analysis, we followed a published protocol for 36 peak preprocessing and Machine Learning (ML), trained on publicly available spectra from South American 37 SARS-CoV-2+ and NCARI samples. In our second sub-analysis, we trained ML models on a peak intensity 38 39 matrix representative of both South American (SA) and Kazakhstan (Kaz) samples. Results: Applying the established MALDI-MS pipeline "as is" resulted in a high detection rate for SARS-40 CoV-2+ samples (91.0%), but low accuracy for NCARI (48.0%) and AC (67.0%) by the top-performing 41 random forest model. After re-training of the ML algorithms on the SA-Kaz peak intensity matrix, the 42 accuracy of detection by the top-performing Support Vector Machine with radial basis function kernel model 43 44 was at 88.0, 95.0 and 78% for the Kazakhstan SARS-CoV-2+, NCARI, and AC subjects, respectively with a SARS-CoV-2 vs. rest ROC AUC of 0.983 [0.958, 0.987]; a high differentiation accuracy was maintained for 45 the South American SARS-CoV-2 and NCARI. 46 47 Conclusions: MALDI-MS/ML is a feasible approach for the differentiation of ARI without a specialized
- 48 sample preparation. The implementation of MALDI-MS/ML in a real clinical lab setting will necessitate
- 49 continuous optimization to keep up with the rapidly evolving landscape of ARI.
- 50

Yegorov et al.

MALDI-MS/ML to detect ARI

Introduction. 51

- The global response to the COVID-19 pandemic has underscored gaps existing in the laboratory-based 52
- 53 diagnosis of acute respiratory infection (ARI)(1). In the early stages of the pandemic, a shortage of rapid and
- inexpensive techniques amenable to modification to adapt to the newly characterized SARS-CoV-2 54
- motivated the search for alternative diagnostic tools. Matrix-assisted laser desorption/ionization mass 55
- spectrometry (MALDI-MS), a technique traditionally employed in proteomics and metabolomics, has 56
- emerged as a promising alternative to molecular and immunochromatography-based assays to detect SARS-57
- CoV-2 (2). Several different MALDI-MS-based approaches involving varied degrees of sample preparation 58
- 59 have been described (2).
- 60 Our clinical laboratory has particularly been interested in the "untargeted" MALDI-MS method, which
- applies Machine Learning (ML) algorithms to discern SARS-CoV-2 infection using MALDI-MS peak 61
- matrices acquired from respiratory samples such as nasopharyngeal swabs (NPS) without a specialized 62
- sample preparation (3–5). Therefore, in this study, we explored the feasibility and accuracy of such 63
- 64 untargeted MALDI-MS/ML in differentiating SARS-CoV-2 from non-COVID acute respiratory infections
- (NCARI) in a clinical laboratory setting in Kazakhstan. 65

Materials and Methods. 66

Study setting. 67

We collected NPS from three participant subgroups: symptomatic SARS-CoV-2+, NCARI and 68 asymptomatic controls (AC). Participants were recruited between May 25, 2020, and December 20, 2022. 69 70 Written consent was obtained from all adult participants in the presence of a study coordinator; parental consent was obtained for participants under 18 years of age. The ARI diagnosis was made based on the 71 presence of at least one of the following: fever, nasal congestion, cough, sore throat, and/or 72 lymphadenopathy. SARS-CoV-2+ participants were recruited from among patients of the Karaganda 73 74 regional clinical hospital, hospitalized with a PCR-confirmed SARS-CoV-2 infection. NCARI participants 75 were recruited at the Karaganda regional clinical hospital and the Karaganda City Centre for Primary

Yegorov et al.

MALDI-MS/ML to detect ARI

76 Healthcare among patients admitted for moderate-severe ARI symptoms. Most (72.4%) NCARI participants

77 were PCR-positive for common respiratory viruses (adenovirus, seasonal coronaviruses, bocavirus,

- 78 parainfluenza viruses, respiratory syncytial virus, rhinovirus, influenza or metapneumovirus) or bacteria
- 79 (Chlamydia pneumoniae or Mycoplasma pneumoniae). Samples were collected around day 3 (median, IQR
- 80 [2-4]) and day 5 (median, IQR [3-7]) post-symptom onset for the SARS-CoV-2+ and NCARI participants,
- 81 respectively. The AC sub-group was recruited from amidst the Karaganda University employees. The SARS-
- 82 CoV-2 infection status was confirmed in the research lab for all samples using SARS-CoV-2 PCR as
- described earlier [6, 7]. All samples were frozen at -80C until processing.
- 84 In addition to the MALDI-MS spectra obtained from clinical samples in Kazakhstan, we incorporated into
- 85 our analysis the publicly available MALDI-MS data from South America (3).

86 MALDI-MS analysis.

87 Within feasible limits, we closely followed the published methodology for sample preparation, spectra

88 acquisition and preprocessing (3), with only minor modifications as specified. Spectral acquisition was

89 performed on the MicroFlex LT v. 3.4 instrument (Bruker Daltonics, Bremen, Germany) equipped with a

90 pulsed UV laser (N2 laser with 337 nm wavelength, 150 microJ pulse energy, 3 ns pulse width and 20 Hz

91 repetition rate). After thawing at room temperature, samples were spotted onto the steel target plate at 0.5 μ l,

92 covered with 0.5 μ l of the HCCA matrix (a solution containing α -cyano-4-hydroxycinnamic acid diluted in

93 acetonitrile, 2.5% trifluoroacetic acid and nuclease-free water) and then air dried. The target plate was then

loaded into the instrument. Spectra were generated by summing 500 single spectra (10 * 50 shots) in the

- range between 3 and 20 kDa, operating in positive-ion linear mode using a18-20 kV acceleration voltage, by
- shooting the laser at random positions on the target spot.

97 Spectral preprocessing.

98 Raw MALDI-MS files (Bruker) were uploaded and subsequently preprocessed in R (v. 4.3.0) using

99 MALDIquantForeign and MALDIquant (6). To ensure consistency in peak processing with the original

100 untargeted protocol (3), we used the R scripts generously shared by the authors. Briefly, the spectra were

Yegorov et al.

MALDI-MS/ML to detect ARI

trimmed to a 3–15.5 kDa range, square-root transformed, and smoothened via the Savitzky–Golay method.
Baseline correction was done using the TopHat algorithm and intensity normalization was done via total ion
current calibration as implemented in MALDIquant. Peak detection was performed using a signal-to-noise
ratio of 2 and a halfWindowSize of 10, and the peaks were binned with a tolerance of 0.003. Peak binning
was performed in two stages to avoid any additional calibration differences. First, each group spectra were
binned separately, and peak filtration was performed, keeping only those peaks that were present in 80% of
the spectra of each group. Subsequently, all peaks were binned together. The resulting peak intensity matrix

108 was used for the downstream analyses.

109 In Analysis I, to assess the models trained on the South American samples from the source study (3), we

110 made slight modifications to the sample preprocessing protocol as follows. To ensure that we are comparing

111 the same 88 peaks, we employed the "reference" method for peak binning using the median values of the

spectra and peaks obtained by Nachtigall *et al.* as a reference and eliminated the filtering procedure for each

113 subgroup. In Analysis II, we constructed a *de novo* peak matrix representative of the combined South

114 America and Kazakhstan dataset using the script provided by Nachtigall *et al.*

115 **Principal component and hierarchical cluster analyses.**

PCA was performed using R FactoMineR and factoextra packages. The hierarchical cluster analysis was done by first calculating a distance matrix using the Euclidean method and clustering samples via the unweighted paired group with arithmetic mean (UPGMA) method. Dendrograms were generated using ggtree and ggtreeExtra R packages.

120 Machine learning and statistical analysis.

121 We implemented a total of seven ML algorithms, six of which were used in the earlier study [5] (DT

122 (Decision Tree - Quinlan's C5.0 algorithm), KNN (k-Nearest Neighbors), NB (Naive Bayes), RF (Random

123 Forest), SVM-L (Support Vector Machine with linear kernel), SVM-R (Support Vector Machine with radial

basis function kernel) plus an additional algorithm XGBoost (eXtreme Gradient Boosting). Analysis 1 was

executed by closely following the earlier protocol, with training performed on South American SARS-CoV-

Yegorov et al.

MALDI-MS/ML to detect ARI

126	2+ and NCARI spectra. Since the training step of analysis II incorporated three sub-groups, i.e. AC samples
127	in addition to the SARS-CoV-2+ and NCARI, the analysis pipeline was modified as outlined below to
128	accommodate this change.

Initially, we split the entire sample into two distinct groups: the training dataset, consisting of 80% of 129 130 samples, and the test group, which accounted for the remaining 20%. In line with Nachtigall *et al* [5], we 131 conducted a training process using a five-fold (outer) nested repeated (five times) ten-fold (inner) crossvalidation with a randomized stratified splitting approach. To optimize the performance of each algorithm, 132 we tested 20 hyperparameters in the inner loop of the cross-validation approach, using a random search 133 134 method. This process was repeated 20 times to ensure robustness and reliability of the model. We selected the best models based on their area under the curve (AUC) score, which is a common metric for evaluating 135 binary-classification model performance, using the Caret R package. In addition, model performance was 136 assessed using several other classification metrics, including F-measure, recall, accuracy, specificity, 137 138 sensitivity, and positive and negative predictive values in the vardstick R package; differences across the sub-groups were assessed using the Mann-Whitney U non-parametric test in R. 139

140 Role of the funding source

141 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of142 the manuscript.

143

144 **Results**

- 145 The primary objective of the study was to assess the capacity of the MALDI-MS approach to detect SARS-
- 146 CoV-2 infection within a heterogeneous mix of SARS-CoV-2+, NCARI and AC samples (Table 1).

147

148

Yegorov et al.

MALDI-MS/ML to detect ARI

Characteristic	Overall, N = 252	SARS-COV- 2+ 2021, N = 108	SARS-COV-2+ 2022, N = 7	NCARI, N=98	AC, N=39	p-value*		
Age, years, median (IQR)	38.0 (18.0,60. 0)	61.0 (48.0,69.0)	3 (1.0, 37.0)	8.0 (2.0, 35.0)	34.0 (25.0, 47.0)	<0.001		
Male sex, n (%)	114 (45.2%)	49 (45.4%)	6 (85,7 %)	38 (38,8%)	21 (53.8%)	<0. 001		
Kazakh ethnicity, n (%)	116 (46%)	26 (24.1%)	5 (71,4%)	61 (62.2%)	24 (61.5%)	<0.001		
Any comorbidities	104 (41.2%)	72 (66.6%)	1 (14,2%)	15 (15.3 %)	14 (35.9%)	<0.001		

150
Table 1. Demographic characteristics of participants.

151

152 * Differences across the groups were assessed using Kruskal-Wallis or Pearson's Chi-squared tests.

153

154 Therefore, we performed two independent analyses (Figure 1). In the first analysis, we assessed the

155 performance of the Nachtigall et al. ML pipeline on the combined pool of samples, both from the original

study (data collected from three South American countries in 2020) and Kazakhstan (data collected in 2021 156

157 and 2022); the ML pipeline in this analysis was trained only on the original South American datasets. In the

second analysis, we retrained the ML algorithm, accounting for the spectra contributed by the samples from 158

Kazakhstan and applied this re-trained ML algorithm to the combined pool of samples. 159

Fig 1. Overall study workflow and description of the analyses. NCARI: non-COVID acute respiratory 160

161 infections; AC: asymptomatic controls; ML: machine learning

162

Analysis I.: Applying the "as is" MALDI-MS pipeline to differentiate 163

ARI samples collected in Kazakhstan. 164

To assess how well the original analysis pipeline (3) would differentiate SARS-CoV-2+ samples within the 165

dataset from Kazakhstan, we replicated the steps for i) MALDI-MS peak selection, ii) ML training and iii) 166

ML assessment. Specifically, we focused on the same MALDI-MS peaks that Nachtigall et al. (3) used in 167

168 their analyses (Table S1). These peaks were derived using a six-step spectra processing workflow including

Yegorov et al.

MALDI-MS/ML to detect ARI

- spectra transformation and smoothing, baseline removing, spectra calibration, peak detection, and peak
- 170 processing.
- 171 We then constructed a peak intensity matrix on the 88 peaks, identical to that used by Nachtigall and
- 172 colleagues (3), for the downstream analysis of a combined dataset incorporating both the South American
- 173 (Table S1) and Kazakhstan samples (Figure 2 and Table S2).

174

- Fig 2. MALDI-MS peak data generated using nasopharyngeal swabs and processed following the
 MALDI-MS/ML pipeline developed by Nachtigall and colleagues (3).
- 177 A-C. representative MALDI-MS spectra from symptomatic SARS-CoV-2+ (A), symptomatic non-SARS-
- 178 CoV-2 (B) and a healthy control sample from Kazakhstan (C). The central line indicates median value of the
- spectra, while the shaded region on either side represents the interquartile interval. Insets depict a range from
- 180 3000 to 5500 m/z encompassing 70% (62/88) of the identified peaks. d. PCA of the combined dataset
- 181 incorporating MALDI-MS data both from Kazakhstan and South America (2020 SARS-CoV+ and
- 182 symptomatic SARS-CoV-2-negative)(3).

- We next explored the selected peaks across the comparison groups by reducing the multidimensionality using principal component analyses and dendrograms. Like Nachtigall et al, we did not detect any obvious clustering by sub-group, emphasizing the need for a more sensitive approach to discern subtle differences in the highly multidimensional MALDI-MS peak data (Figure 2D and 2E, Figures S2-S5). Hence, we then applied to our combined Kazakhstan-South America MALDI-MS peak dataset the original Nachtigall *et al.*
- 189 ML algorithm trained on the original South American samples (3).
- 190 In keeping with earlier results (3), when tested the South American samples alone, SVM-R provided the
- 191 highest ROC AUC, although other models had similarly high-performance characteristics (Table S3 and
- 192 Figure 3A-B) for classifying cases of SARS-CoV-2 and non-SARS-CoV-2.
- 193

Yegorov et al.

MALDI-MS/ML to detect ARI

194 Fig 3. Classification accuracy of the MALDI-ML algorithms assessed on the data from Kazakhstan and South America. 195

- A) Accuracy metrics for each of the seven ML models trained on the South American MALDI-MS data 196
- 197 (Analysis I in the current study) for the differentiation of study sub-groups. B) ROC curves of the top-
- performing RF and SVM-L algorithms (Analysis I). C) Accuracy metrics for each of the seven ML models 198
- 199 trained on the combined South America-Kazakhstan dataset (Analysis II in the current study) for the
- 200 differentiation of study sub-groups. D) ROC curves for the top-performing SVM-R and DT algorithms
- 201 (Analysis II).

202

203 Subsequently, we assessed the performance of the same ML algorithms on samples from Kazakhstan. Here,

we observed a broad variation in the ability of the ML models to discern SARS-CoV-2+ samples. RF had the 204

205 highest percentage of correctly identified 2020-SARS-CoV-2+ samples (91%) (Figure 3A and Table S4,

Figure S6). Notably, the accuracy for 2021 SARS-CoV-2 was <60% for all models, similar to the accuracy 206

207 for identifying NCARI. RF discerned AC with an accuracy of 68%, the highest of all models for this sub-208 group.

Analysis II: Applying the re-trained MALDI/MS-ML to differentiate 209

ARI. 210

To ensure that we include all relevant MALDI-MS signature peaks representative of all sub-groups, we 211

performed peak selection on the entire pool of samples containing samples from both Kazakhstan and South 212

213 America (n=615). A total of 120 peaks were identified and a peak intensity matrix was constructed (Table

- S5). As in Analysis I, PCA and dendrograms did not show any visually apparent clustering of sub-groups 214
- (Figures S7-S10). We then proceeded to train ML models on the combined pool consisting of the 120 peaks, 215
- of which 53 overlapped with the original 88 peaks. 216
- 217 Due to the small sample size of the 2022 subset, the SARS-CoV-2 2021 and 2022 subsets were combined
- 218 prior to testing the model performance. We then assessed the performance of the trained ML algorithm on

Yegorov et al.

MALDI-MS/ML to detect ARI

219 the South America-Kazakhstan dataset. All models demonstrated similarly high-performance characteristics 220 in differentiating SARS-CoV-2+ samples. SVM-R and DT slightly outperformed the other five models in 221 discerning SARS-CoV-2 infection from both NCARI and AC with ROC AUC values of 0.983 [0.958, 0.987] and 0.972 [0.966, 0.979], respectively (Figures 3C-D and Table S4). SVM-R, in particular, differentiated the 222

Kazakhstan SARS-CoV-2+, NCARI, and AC subjects with an accuracy of 88.0, 95.0 and 78.0%,

respectively (Figure 3C). Both SVM-R and DT were also highly accurate at differentiating NCARI and AC 224

sub-groups (Table S4). 225

Discussion 226

223

227 Here we aimed to assess the feasibility of deploying MALDI-MS and ML in a clinical lab to differentiate

SARS-CoV-2 from other ARI, particularly in the context of minimal specialized sample preparation. Our 228

initial application of the original MALDI-MS/ML pipeline, trained on South American samples (3). 229

230 demonstrated reduced efficiency in identifying samples from Kazakhstan. Re-training the ML models to

231 incorporate MALDI peak information from a diverse pool of Kazakhstan samples, including SARS-CoV-2+,

232 NCARI subjects, and asymptomatic controls, led to a significant improvement in detection accuracy. Taken

as a proof-of-concept, our results support the utility of MALDI-MS/ML, especially in the early phases of 233

234 respiratory endemics/pandemics, when limited knowledge is available on the infectious pathogen's identity

and in low-resource environments, where alternative methods may vet be unavailable. 235

236 Our replication studies underscore the importance of considering geographical and population-specific

237 variations in the application of MALDI-MS/ML. The observed differences in the performance of the original

pipeline trained on South American samples may be attributed to the inherent complexity of NPS, which 238

239 contains a mixture of host proteins and diverse microbial species (7.8). The sensitivity and specificity of

240 MALDI-MS/ML may also be affected by variability in immune response to different viral loads and the

241 presence of co-infections (9,10). These challenges emphasize the need for careful evaluation and calibration

242 in the application of MALDI-MS/ML.

Our study has several limitations. The lack of specialized sample preparation, although advantageous for 243 low-resource settings, may introduce variability and noise into the data, a concern raised by other authors 244

Yegorov et al.

MALDI-MS/ML to detect ARI

245 (9,10). Due to a relatively small sample size of the NCARI group, we did not further pursue stratification of this group by the causative agents identified via multiplex PCR. The utility of MALDI-MS/ML in 246 247 differentiating various NCARI would be important to examine in the context of the changing post-pandemic ARI landscape (11). Temporal variation, spanning samples collected over two years (2020-2022), might 248 249 have contributed to a high heterogeneity of our results. The differences across groups regarding the basic demographics may also have a confounding effect on the results. Further validation of the method in a 250 broader clinical context would be necessary to fully assess the potential for real-world application. 251 252 In conclusion, our study provides valuable insights into the potential of MALDI-MS as an accessible 253 laboratory-based diagnostic tool for ARI. While promising, the implementation of MALDI-MS/ML in real clinical lab settings will require further optimization, validation, and continuous adaptation to the evolving 254 epidemiological landscape. Further research is needed to explore the specific components of MALDI-MS 255 spectra that are most informative for differentiating various ARI. Such investigations will contribute to the 256 257 ongoing refinement of this promising diagnostic tool.

258 **Declarations**

259 Ethics approval and consent to participate.

All study procedures were approved by the Research Ethics Board of Karaganda Medical University under
Protocol 12 (approved 45) from 06.04.2020. Written informed consent was obtained from all participants.

262 **Consent for publication**

Authors provide consent for the publication of the manuscript detailed above, including any accompanyingimages or data contained within the manuscript.

265 Availability of data and materials

All raw data and R code are available through Github (https://github.com/dimbage/ML_MALDI-TOF_SARS-

267 CoV-2).

perpetuity. It is made available under a CC-BY 4.0 International license .

Yegorov et al.

MALDI-MS/ML to detect ARI

268 Acknowledgements

- 269 We thank the study participants and clinic staff. We are grateful to Professor Leonardo Santos for sharing the
- 270 R scripts and associated data from their original study.

271 Supplementary information

- 272 All supplementary information can be found in the Appendix.
- 273

274 References.

- Yegorov S, Goremykina M, Ivanova R, Good SV, Babenko D, Shevtsov A, et al. Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study. The Lancet Regional Health – Europe [Internet]. 2021 May 1 [cited 2021 Aug 9];4.
 Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00073-9/abstract
- Spick M, Lewis HM, Wilde MJ, Hopley C, Huggett J, Bailey MJ. Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry. Metabolism Clinical and Experimental [Internet]. 2022 Jan 1 [cited 2022 Dec 13];126. Available from:
- 282 https://www.metabolismjournal.com/article/S0026-0495(21)00222-5/fulltext
- 3. Nachtigall FM, Pereira A, Trofymchuk OS, Santos LS. Detection of SARS-CoV-2 in nasal swabs using
 MALDI-MS. Nat Biotechnol. 2020 Oct;38(10):1168–73.
- Deulofeu M, García-Cuesta E, Peña-Méndez EM, Conde JE, Jiménez-Romero O, Verdú E, et al.
 Detection of SARS-CoV-2 Infection in Human Nasopharyngeal Samples by Combining MALDI-TOF
 MS and Artificial Intelligence. Front Med (Lausanne). 2021;8:661358.
- 5. Tran NK, Howard T, Walsh R, Pepper J, Loegering J, Phinney B, et al. Novel application of automated
 machine learning with MALDI-TOF-MS for rapid high-throughput screening of COVID-19: a proof of
 concept. Sci Rep. 2021 Apr 15;11(1):8219.
- 6. Gibb S, Strimmer K. MALDIquant: a versatile R package for the analysis of mass spectrometry data.
 Bioinformatics. 2012 Sep 1;28(17):2270–1.
- 7. Rajagopala SV, Bakhoum NG, Pakala SB, Shilts MH, Rosas-Salazar C, Mai A, et al. Metatranscriptomics
 to characterize respiratory virome, microbiome, and host response directly from clinical samples. Cell
 Rep Methods. 2021 Oct 25;1(6):100091.
- Sandybayev NT, Beloussov VY, Strochkov VM, Solomadin MV, Granica J, Yegorov S. The nasopharyngeal virome in adults with acute respiratory infection [Internet]. bioRxiv; 2023 [cited 2023
 Aug 29]. p. 2023.08.21.554191. Available from: https://www.biorxiv.org/content/10.1101/2023.08.21.554191v1
- 9. Iles RK, Zmuidinaite R, Iles JK, Carnell G, Sampson A, Heeney JL. Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work.
 Diagnostics (Basel). 2020 Sep 24;10(10):746.

Yegorov et al.

MALDI-MS/ML to detect ARI

- Renuse S, Vanderboom PM, Maus AD, Kemp JV, Gurtner KM, Madugundu AK, et al. A mass 303 10. spectrometry-based targeted assay for detection of SARS-CoV-2 antigen from clinical specimens. 304 EBioMedicine. 2021 Jul;69:103465. 305
- 306 11. Sandybayev N, Beloussov V, Strochkov V, Solomadin M, Granica J, Yegorov S. Characterization of 307 viral pathogens associated with symptomatic upper respiratory tract infection in adults during a low COVID-19 transmission period. PeerJ. 2023;11:e15008. 308

309



Fig 2 Figure 2





Fig 3 Figure 3



Figure 1